S258
Clinical - Breast
ESTRO 2026
ten of these patients received a sequential boost. Basic demographic information, treatment details and dosimetric findings are provided in Table 1. Twenty-six patients (56.5%) had either pT3 or pN+ disease, and nine more patients (19.6%) had cT3 or cN+ at baseline which got downstaged with neo-adjuvant chemotherapy (NACT). These 35 patients (76.1%) received RNI to level III and IV lymph nodes. Most important acute radiation toxicities noted were dermatitis [45 patients (97.8%) with grade 1 and 1 patient (2.2%) with grade 2] and dysphagia [3 patients (6.5%) with grade 1 and 1 patient (2.2%) with grade 2]. After a median follow-up of 13.9 months, there have been 1 local recurrence at scar site and 1 patient progressed with brain metastasis. 1-year Loco-regional control (LRC) and 1-year Disease-free survival (DFS) were both 96.8% [95%CI 93.6 – 100] (Fig. 1).
Conclusion: Five-fraction ultra-hypofractionated radiotherapy in early breast cancer is feasible with low rates of low- grade acute toxicities and acceptable dosimetric outcomes. Early clinical outcomes are also favourable, although longer follow-ups are required. Keywords: ultra-hypofractionation, radiotherapy, RNI Digital Poster 1791 Who Can Hold Their Breath? Understanding Patient’s Needs and Screening for Deep Inspiration Breath Hold Suitability: A Retrospective Evaluation Kathleene Dower 1,2 , Haryana M Dhillon 3 , Kate Mueller 4,5 , Moira O'Connor 2 , Julan Amalaseelan 1 , Georgia KB Halkett 2 1 Radiation Oncology, North Coast Cancer Institute, Lismore, Australia. 2 Faculty of Health Sciences, Curtin University, Perth, Australia. 3 School of Psychology, University of Sydney, Sydney, Australia. 4 Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Australia. 5 Research Office, Northern New South Wales Local Health District, Lismore, Australia Purpose/Objective: Many patients struggle to sustain Deep Inspiration Breath Hold (DIBH) for their breast cancer radiation
Made with FlippingBook - Share PDF online